COATED FAMOTIDINE PARTICLE

1 . A coated famotidine particle having at least a core and a coating layer, wherein

the particle core comprises from 5% to 20% w/w of famotidine, from 70% to 93% w/w of a first filler and from 2% to 10% w/w of a first binder, and

the coating layer is substantially free from famotidine and comprises a second filler and a second binder,

wherein the first and second filler may be similar or different; and selected from the group consisting of lactose, microcrystalline cellulose, starch, dextrose, mannitol, sorbitol, xylitol, maltitol or combination thereof and

wherein the first and second binder may be similar or different, and selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, polyvinylpyrrolidone, Sodium Carboxymethylcellulose, Ethyl cellulose, Polyvinyl alcohol-povidone copolymer, pregelatinized starch, or combination thereof.

2 . The coated famotidine particle according to claim 1 , wherein the first and second filler is first and second binder is lactose and the hydroxypropylmethylcellulose.

3 . The coated famotidine particle according to claim 1 , wherein the core comprises a flowing agent selected from the group consisting of Silica, colloidal silica, fumed silica, aluminometasilicate, preferably a colloidal silica such as amorphous silicon dioxide.

4 . The coated famotidine particle according to claim 1 , wherein the coating layer accounts for 10% to 30% w/w of the particle total weight.

5 . The coated famotidine particle according to claim 1 , wherein said core and coating layer comprise:

from 10% to 15% w/w of Famotidine, preferably from 12% to 14% w/w,

from 3% to 10% w/w of Binders, preferably from 5% to 6.5% w/w,

from 75% to 90% w/w of Fillers, preferably from 80% to 83% w/w,

from 0.1% to 1% w/w of a Flowing agent, preferably from 0.5% to 0.7% w/w,

wherein all % w/w are respective to the coated famotidine particle total weight.

6 . The coated famotidine particle according to claim 1 , wherein the coating layer has a thickness between 50 μm to 300 μm.

7 . The coated famotidine particle according to claim 1 , wherein the particle size is between 200 μm to 500 μm.

8 . A solid dosage form comprising the coated famotidine particle according to claim 1 , wherein the coated famotidine particle represents from 3% to 6% w/w of the solid dosage form total weight.

9 . The solid dosage form according to claim 8 , comprising in addition to the coated famotidine particle an antacid, wherein the antacid represents from 50% to 60% of the dosage form total weight.

10 . The solid dosage form according to claim 8 , wherein the antacid is selected from the group consisting of calcium carbonate, sodium bicarbonate, magnesium hydroxide, aluminum oxide, aluminum hydroxide, magnesium oxide, magnesium carbonate, aluminum phosphate, magaldrate, magnesium trisilicate, bismuth salicylate, bismuth subsalicylate or combination thereof.

11 . The solid dosage form according to claim 8 , wherein the famotine content is from 50 mg to 200 mg.

12 . Method for manufacturing a coated famotidine particle as disclosed in claim 1 , comprising the following steps:

Spraying a first binder on a mixture of famotidine and a granulation batch of a first filler to obtain wet famotidine particles core,

Spraying a second binder, while mixing said wet famotidine particles core and a layering batch comprising a second filler, to coat the famotidine particle core into a coated famotidine particle,

wherein the first and second filler may be similar or different; and the first and second binder may be similar or different.

13 . The method according to claim 12 , wherein the first filler and the second filler used respectively in the granulation batch and the layering batch are the same.

14 . The method according to claim 12 , wherein the first binder and the second binder, respectively sprayed on the famotidine and the granulation batch, and sprayed on the wet famotidine particles core and the layering batch, are the same.

15 . Use of a coated famotidine particle according to claim 1 , for the manufacture of a solid dosage form for the treatment of a disease or disorder in the gastrointestinal tract such as heartburn, bothersome gas symptoms, indigestion, dyspepsia, impaired digestion, upper abdominal fullness, nausea, belching, upper abdominal pain, gastroesophageal reflux disease (GERD) or gastritis.

16 . A coated famotidine particle according to claim 1 for use as a treatment of a disease or disorder in the gastrointestinal tract such as heartburn, bothersome gas symptoms, indigestion, dyspepsia, impaired digestion, upper abdominal fullness, nausea, belching, upper abdominal pain, gastroesophageal reflux disease (GERD) or gastritis.

17 . A method of treating a disease or disorder in the gastrointestinal tract by use of the coated famotidine particle according to claim 1 .

18 . A solid dosage form according to claim 8 for use as a treatment of a disease or disorder in the gastrointestinal tract such as heartburn, bothersome gas symptoms, indigestion, dyspepsia, impaired digestion, upper abdominal fullness, nausea, belching, upper abdominal pain, gastroesophageal reflux disease (GERD) or gastritis.

19 . A method of treating a disease or disorder in the gastrointestinal tract by use of the solid dosage form according to claim 8 .